Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lincy S Lal

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
American Health & Drug Benefits|September 18, 2015
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic RegimensLee Schwartzberg, Brooke Harrow, Lincy S Lal, et al.
Cancer Medicine|March 27, 2020
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysisYunes Doleh, Lincy S Lal, Cori Blauer-Petersen, et al.
Obesity Surgery|July 23, 2013
Racial disparity in short-term outcomes after gastric bypass surgeryLily K Cheung, Lincy S Lal, Diana S-L Chow, et al.
Current Medical Research and Opinion|February 22, 2021
Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysisJingbo Yu, Lincy S Lal, Amy Anderson, et al.
Community Oncology|August 11, 2012
Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer centerTisha M Felder, Lincy S Lal, Charles L Bennett, et al.
Lung Cancer (Auckland, N.Z.)|November 2, 2017
Comparative effectiveness and safety of <i>nab</i>-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology settingRaja Mudad, Manish B Patel, Sandra Margunato-Debay, et al.
Cancer Reports (Hoboken, N.J.)|September 8, 2021
Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims studyLincy S Lal, Abdalla Aly, Lisa B Le, et al.
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Managing specialty medication services through a specialty pharmacy program: the case of oral renal transplant immunosuppressant medicationsSuzanne Tschida, Saad Aslam, Tanvir T Khan, et al.
Annals of Hematology|September 10, 2021
Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysisPallavi Patwardhan, Adrienne Landsteiner, Lincy S Lal, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 12, 2011
Economic impact of stereotactic radiosurgery for malignant intracranial brain tumorsLincy S Lal, Luisa Franzini, Janki Panchal, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
American Health & Drug Benefits|September 18, 2015
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic RegimensLee Schwartzberg, Brooke Harrow, Lincy S Lal, et al.
Cancer Medicine|March 27, 2020
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysisYunes Doleh, Lincy S Lal, Cori Blauer-Petersen, et al.
Obesity Surgery|July 23, 2013
Racial disparity in short-term outcomes after gastric bypass surgeryLily K Cheung, Lincy S Lal, Diana S-L Chow, et al.
Current Medical Research and Opinion|February 22, 2021
Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysisJingbo Yu, Lincy S Lal, Amy Anderson, et al.
Community Oncology|August 11, 2012
Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer centerTisha M Felder, Lincy S Lal, Charles L Bennett, et al.
Lung Cancer (Auckland, N.Z.)|November 2, 2017
Comparative effectiveness and safety of <i>nab</i>-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology settingRaja Mudad, Manish B Patel, Sandra Margunato-Debay, et al.
Cancer Reports (Hoboken, N.J.)|September 8, 2021
Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims studyLincy S Lal, Abdalla Aly, Lisa B Le, et al.
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Managing specialty medication services through a specialty pharmacy program: the case of oral renal transplant immunosuppressant medicationsSuzanne Tschida, Saad Aslam, Tanvir T Khan, et al.
Annals of Hematology|September 10, 2021
Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysisPallavi Patwardhan, Adrienne Landsteiner, Lincy S Lal, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 12, 2011
Economic impact of stereotactic radiosurgery for malignant intracranial brain tumorsLincy S Lal, Luisa Franzini, Janki Panchal, et al.
Pageof 6